Abstract:Despite the efforts devoted to drug discovery and development, the number of new drug approvals have been decreasing. Specifically, cardiovascular developments have been showing amongst the lowest levels of approvals. In addition, concerns over the adverse effects of drugs to the cardiovascular system have been increasing and resulting in failure at the preclinical level as well as withdrawal of drugs post-marketing. Besides factors such as the increased cost of clinical trials and increases in the requirements and the complexity of the regulatory processes, there is also a gap between the currently existing pre-clinical screening methods and the clinical studies in humans. This gap is mainly caused by the lack of complexity in the currently used 2D cell culture-based screening systems, which do not accurately reflect human physiological conditions. Cell-based drug screening is widely accepted and extensively used and can provide an initial indication of the drugs' therapeutic efficacy and potential cytotoxicity. However, in vitro cell-based evaluation could in many instances provide contradictory findings to the in vivo testing in animal models and clinical trials. This drawback is related to the failure of these 2D cell culture systems to recapitulate the human physiological microenvironment in which the cells reside. In the body, cells reside within a complex physiological setting, where they interact with and respond to neighboring cells, extracellular matrix, mechanical stress, blood shear stress, and many other factors. These factors in sum affect the cellular response and the specific pathways that regulate variable vital functions such as proliferation, apoptosis, and differentiation. Although pre-clinical in vivo animal models provide this level of complexity, cross species differences can also cause contradictory results from that seen when the drug enters clinical trials. Thus, there is a need to better mimic human physiological conditions in pre-clinical studies to improve the efficiency of drug screening. A novel approach is to develop 3D tissue engineered miniaturized constructs in vitro that are based on human cells. In this review, we discuss the factors that should be considered to produce a successful vascular construct that is derived from human cells and is both reliable and reproducible.

Engineering Three-Dimensional Cardiac Microtissues for Potential Drug Screening Applications.

Engineering Three-Dimensional Microenvironments Towards in Vitro Disease Models of the Central Nervous System

Engineered human cardiac tissues for modeling heart diseases

Engineering Cardiac Tissue for Advanced Heart‐on‐a‐chip Platforms

Strategies for Constructing Pluripotent Stem Cell- and Progenitor Cell-Derived Three-Dimensional Cardiac Micro-Tissues.

3D Tissue-Engineered Vascular Drug Screening Platforms: Promise and Considerations

Advances in 3D bioprinting technology for cardiac tissue engineering and regeneration

3D bioprinting in cardiac tissue engineering

Biomimetic Cardiac Microsystems for Pathophysiological Studies and Drug Screens

Abstract 368: Ex vivo Fabrication of Heart Tissue Model With Perfusable Blood Vessels Using Cell Sheet

Industrialization of three-dimensional hiPSC-cardiac microtissues for high-throughput cardiac safety and drug discovery screening

Emerging Technologies for Cardiac Tissue Engineering and Artificial Hearts

Advances in three-dimensional bioprinted stem cell-based tissue engineering for cardiovascular regeneration

Accelerating cardiovascular research: recent advances in translational 2D and 3D heart models

Human Pluripotent Stem Cell-Derived Cardiac Cells: Application in Disease Modeling, Cell Therapy, and Drug Discovery

3D Bioprinting Technology – One Step Closer Towards Cardiac Tissue Regeneration

3D-bioprinted cardiac tissues and their potential for disease modeling

Microfabrication of liver and heart tissues for drug development

Advances in Multidimensional Cardiac Biosensing Technologies: From Electrophysiology to Mechanical Motion and Contractile Force

Cardiac tissue engineering: state of the art.

Three-Dimensional Bioprinting in Cardiovascular Disease: Current Status and Future Directions